Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 350

1.

HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.

Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, Dupuis B, Parker RL.

Mod Pathol. 2001 Nov;14(11):1079-86.

2.
3.

Comparison of immunohistochemical and fluorescence in situ hybridization assessment for HER-2/neu status in Taiwanese breast cancer patients.

Kuo SJ, Wang BB, Chang CS, Chen TH, Yeh KT, Lee DJ, Yin PL, Chen M.

Taiwan J Obstet Gynecol. 2007 Jun;46(2):146-51.

4.

HER-2/neu evaluation by immunohistochemistry and fluorescence in situ hybridization in breast cancer: implications for daily laboratory practice.

Larsimont D, Di Leo A, Rouas G, Paesmans M, Ferreira-Filho F, Bernard C, Cardoso F, Verhest A, Piccart MJ, Gancberg D.

Anticancer Res. 2002 Jul-Aug;22(4):2485-90.

PMID:
12174949
6.
7.

Accurately assessing her-2/neu status in needle core biopsies of breast cancer patients in the era of neoadjuvant therapy: emerging questions and considerations addressed.

D'Alfonso T, Liu YF, Monni S, Rosen PP, Shin SJ.

Am J Surg Pathol. 2010 Apr;34(4):575-81. doi: 10.1097/PAS.0b013e3181d65639.

PMID:
20216378
8.
9.

Evaluating HER2 amplification and overexpression in breast cancer.

Bartlett JM, Going JJ, Mallon EA, Watters AD, Reeves JR, Stanton P, Richmond J, Donald B, Ferrier R, Cooke TG.

J Pathol. 2001 Nov;195(4):422-8.

PMID:
11745673
10.
11.

HER-2 gene amplification by chromogenic in situ hybridisation (CISH) compared with fluorescence in situ hybridisation (FISH) in breast cancer-A study of two hundred cases.

Sáez A, Andreu FJ, Seguí MA, Baré ML, Fernández S, Dinarés C, Rey M.

Breast. 2006 Aug;15(4):519-27. Epub 2005 Nov 14.

PMID:
16290155
12.

Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing.

Gancberg D, Järvinen T, di Leo A, Rouas G, Cardoso F, Paesmans M, Verhest A, Piccart MJ, Isola J, Larsimont D.

Breast Cancer Res Treat. 2002 Jul;74(2):113-20.

PMID:
12186371
13.

Validation of the 4B5 rabbit monoclonal antibody in determining Her2/neu status in breast cancer.

van der Vegt B, de Bock GH, Bart J, Zwartjes NG, Wesseling J.

Mod Pathol. 2009 Jul;22(7):879-86. doi: 10.1038/modpathol.2009.37. Epub 2009 Mar 20.

14.

Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression.

Tsuda H, Akiyama F, Terasaki H, Hasegawa T, Kurosumi M, Shimadzu M, Yamamori S, Sakamoto G.

Cancer. 2001 Dec 15;92(12):2965-74.

PMID:
11753973
15.

Detection of low level HER-2/neu gene amplification in prostate cancer by fluorescence in situ hybridization.

Liu HL, Gandour-Edwards R, Lara PN Jr, de Vere White R, LaSalle JM.

Cancer J. 2001 Sep-Oct;7(5):395-403.

PMID:
11693898
16.

HER-2/neu analysis in breast cancer bone metastases.

Zustin J, Boddin K, Tsourlakis MC, Burandt E, Mirlacher M, Jaenicke F, Izbicki J, Ruether W, Rueger JM, Bokemeyer C, Simon R, Sauter G.

J Clin Pathol. 2009 Jun;62(6):542-6. doi: 10.1136/jcp.2008.059717.

PMID:
19474354
17.

Histopathologic characteristics predicting HER-2/neu amplification in breast cancer.

Prati R, Apple SK, He J, Gornbein JA, Chang HR.

Breast J. 2005 Nov-Dec;11(6):433-9.

PMID:
16297088
18.
19.

Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.

Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B, Sastre-Garau X.

Mod Pathol. 2000 Nov;13(11):1238-43.

20.

HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer.

Harbeck N, Ross JS, Yurdseven S, Dettmar P, Pölcher M, Kuhn W, Ulm K, Graeff H, Schmitt M.

Int J Oncol. 1999 Apr;14(4):663-71.

PMID:
10087312

Supplemental Content

Support Center